DUSP6 and synovial sarcoma: Therefore, we conclude that prolonged exposure to pazopanib induces downregulation of DUSP6 by an unknown mechanism, and sustained phosphorylation of ERK1/2 promotes cell cycle progression and proliferation in SS cells.